Adjuvant targeted therapy in patients with skin melanoma: evidence from Russian real-world clinical practice (RATIONALE study)
Authors:
- Igor V. SamoylenkoISIgor V. Samoylenko
- Kristina V. OrlovaKOKristina V. Orlova
- Sergey V. SharovSSSergey V. Sharov
- Alexander V. SultanbaevASAlexander V. Sultanbaev
- Arshak A. AkopyanAAArshak A. Akopyan
- Nadezhda V. LeushinaNLNadezhda V. Leushina
- Akhmed Y. M.Z. Abdelgafur OmarAOAkhmed Y. M.Z. Abdelgafur Omar
- Ilya A. PokataevIPIlya A. Pokataev
- Tatiana V. ChupriianovaTCTatiana V. Chupriianova
- Olga V. RomachukOROlga V. Romachuk
- Aleksandr V. ShkradiukASAleksandr V. Shkradiuk
Open Access
- 5 December 2025
- journal article
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 27 (3) , 246-257
Abstract
Background. Adjuvant targeted therapy (ATT) with a combination of dabrafenib and trametinib after radical surgical treatment in patients with stage III skin melanoma (SM) with a BRAF V600 mutation reduces the risk of disease recurrence. The effectiveness of this approach has been demonstrated in randomized clinical trials, and also confirmed in several large non-Russian real-world (RW) studies. Aim. To evaluate, in RW settings, the effectiveness of ATT with a combination of dabrafenib and trametinib after definitive surgical treatment in patients with BRAF V600-positive SM in Russia. Materials and methods. The RATIONALE study is a prospective, non-interventional, multicenter RW study. The follow-up duration for the study was 1 year. Patients with SM older than 18 years who had previously started dabrafenib and trametinib therapy no more than 8 weeks prior to Visit 1 were included in the study. The paper presents results from the analysis of Cohort 1 only (patients who received dabrafenib and trametinib in the adjuvant setting). Results. The cohort included 214 patients with BRAF V600-mutated SM of stages IIIA–D and IV resectable. At the time of therapy initiation, the majority of patients were stage IIIc (54.7%) or IIIb (22.0%). The most common mutation – BRAF V600E – occurred in 66.3% of cases, while the second most common variant – BRAF V600 not otherwise specified – was detected in 31.3%. One-year overall survival for all included patients was 94%, one-year relapse-free survival was 84%, and one-year distant metastasis-free survival was 86%. No previously listed adverse events were reported. Adverse events led to therapy discontinuation in only 11.7% of cases. ATT did not reduce patients' quality of life. In the subgroup analysis, the effectiveness of the combination of dabrafenib and trametinib after removal of distant metastases (equivalent to stage IV resectable) was found, in particular, the one-year relapse-free survival rate was 83%, and the one-year overall survival rate was 100%, which is comparable to these indicators for stage IIIB-D (72–86 and 78–100%, respectively). Conclusion. The effectiveness and favorable safety profile of the combination of dabrafenib and trametinib in ATT after radical surgical treatment was confirmed in a population of Russian patients with SM in the RW settings.Keywords
This publication has 19 references indexed in Scilit:
- Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III MelanomaNew England Journal of Medicine, 2024
- 1100P Anti-PD1 + low-dose anti-CTLA4 immunotherapy pathological response rate in patients with stage III resectable melanoma: Phase III NEOMIMAJOR trial interim analysisAnnals of Oncology, 2024
- Influence of adjuvant therapies on organ‐specific recurrence of cutaneous melanoma: A multicenter study on 1383 patients of the prospective DeCOG registry ADORegInternational Journal of Cancer, 2024
- Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort studyeClinicalMedicine, 2023
- Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced MelanomaNew England Journal of Medicine, 2023
- Neoadjuvant relatlimab and nivolumab in resectable melanomaNature, 2022
- Cumulative incidence and risk factors of brain metastasis for acral and mucosal melanoma patients with stages I–IIIEuropean Journal of Cancer, 2022
- Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event management algorithm in patients treated with adjuvant dabrafenib plus trametinib: Primary results of COMBI-APlusEuropean Journal of Cancer, 2022
- Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III MelanomaNew England Journal of Medicine, 2020
- Adjuvant Dabrafenib plus Trametinib in Stage IIIBRAF-Mutated MelanomaNew England Journal of Medicine, 2017